Brief: FDA Announces Six Additional Awardees Under The CNPV Pilot Program
06/11/2025 19:15
Nov 6 (Reuters) - FDA: FDA: SIX ADDITIONAL AWARDEES UNDER THE COMMISSIONER’S NATIONAL PRIORITY VOUCHER (CNPV) PILOT PROGRAM FDA: ZONGERTINIB FOR HER2 LUNG CANCER, DOSTARLIMAB FOR RECTAL CANCER SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS FDA: CASGEVY FOR SICKLE CELL DISEASE, ORFORGLIPRON FOR OBESITY AND RELATED HEALTH CONDITIONS SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS FDA: WEGOVY FOR OBESITY, BEDAQUILINE FOR DRUG-RESISTANT TUBERCULOSIS IN YOUNG CHILDREN SELECTED FOR SECOND BATCH OF NATIONAL PRIORITY VOUCHERS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31